Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes

This study has been completed.
Sponsor:
Collaborators:
Manitoba Medical Service Foundation
Manitoba Institute of Child Health
The Health Sciences Centre Medical Staff Council
Information provided by:
Canadian Diabetes Association
ClinicalTrials.gov Identifier:
NCT00141986
First received: September 1, 2005
Last updated: April 25, 2011
Last verified: September 2005
  Purpose

Type 1 diabetes is a common chronic disease of childhood. It is not yet preventable. Multiple daily injections of insulin, tests of blood sugar, and careful dietary planning are required lifelong to prevent long-term complications such as blindness and kidney failure. Recent studies of potential risk factors in children with diabetes, along with studies revealing the immunologic properties of vitamin D, and experiments in animals suggest higher doses of vitamin D may prevent type 1 diabetes. For proof for human children, a randomized trial will compare groups at risk randomly assigned to receive either the usual vitamin D supplement or a higher amount, 2000 IU daily. This initial study is a small scale test of procedures.


Condition Intervention Phase
Type 1 Diabetes
Dietary Supplement: vitamin D3
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Pilot Trial of Vitamin D for the Prevention of Type 1 Diabetes

Resource links provided by NLM:


Further study details as provided by Canadian Diabetes Association:

Primary Outcome Measures:
  • change in 25(OH)D from baseline [ Time Frame: at baseline (1 month of age), 2 months of age, 6 months of age, 9 months of age, 1 year of age ] [ Designated as safety issue: Yes ]
    25-hydroxyvitamin D levels


Secondary Outcome Measures:
  • renal ultrasound [ Time Frame: 1 year of age ] [ Designated as safety issue: Yes ]
    to detect nephrocalcinosis

  • bone densitometry [ Time Frame: at 6 months and 1 year of age ] [ Designated as safety issue: No ]
  • diabetes autoantibody levels [ Time Frame: 1 year of age ] [ Designated as safety issue: No ]
    GADA, ICA-512, IAA

  • recruitment and retention rates [ Time Frame: 1 year of age ] [ Designated as safety issue: No ]
  • Change from baseline in serum calcium levels [ Time Frame: at baseline (1 month of age), 2 months of age, 6 months of age, 9 months of age, 1 year of age ] [ Designated as safety issue: Yes ]
  • changes in urine calcium:creatinine ratio [ Time Frame: monthly in the first year of life ] [ Designated as safety issue: Yes ]

Enrollment: 9
Study Start Date: November 2003
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D—higher dose
Vitamin D 2000 IU per os once daily
Dietary Supplement: vitamin D3
2000 IU per day
Other Name: cholecalciferol
Active Comparator: Vitamin D—lower dose
Vitamin D 400 IU per os once daily
Dietary Supplement: vitamin D3
400 IU per os once daily
Other Name: Cholecalciferol

Detailed Description:

Type 1 diabetes is a multifactorial disease with both strong genetic and non-genetic components of disease susceptibility. The uniquely strong genetic risk factor region, the human leukocyte antigen region on chromosome 6p, contributes approximately half of the genetic component and can be used for screening for diabetes risk. For example, individuals with the highest risk compound heterozygote genotype comprise 2% of the general population, but have a twenty fold increased risk for type 1 diabetes with an absolute risk of approximately 7% by age 15 years.

Studies of the non-inherited component of diabetes susceptibility implicate external environmental factors operating in the first year of life, suggesting the possibility to reverse the trend with the correct intervention. Recent data suggest that the vitamin D system is a potentially important target for therapeutic intervention to prevent type 1 diabetes. These data include epidemiological studies showing that vitamin D supplementation in infancy is associated with a substantially decreased subsequent risk of the disease, and animal work in the non-obese diabetes mouse model of autoimmune diabetes showing that the incidence of autoimmune diabetes increases when the animals are nutritionally deprived of vitamin D, and that the disease can be prevented using 1,25-dihydroxyvitamin D, and non-hypercalcemic vitamin D analogues. In vitro experiments suggest that the prevention seen in NOD mice may be due to combined effects of vitamin D on antigen presenting cells and activated T-cells.

Based on these epidemiological and animal model studies, we hypothesize that administration during infancy of cholecalciferol, the usual nutritional supplement form of vitamin D, at the increased dose of 2000 IU/day (instead of the current practice of 400 IU/day) will prevent type 1 diabetes in children from the general population at increased genetic risk.

The main objective of this proposal is to pilot a two-arm randomized controlled trial comparing these two doses. The participants are infants from the general population identified at increased genetic risk for type 1 diabetes by cord blood or filter paper blood spot HLA class II genetic screening. The study will measure key safety, compliance and pharmacokinetic, surrogate efficacy, and process outcomes including growth parameters, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels, calcium levels in blood and urine, bone mineral content and body composition by densitometry, diabetes-related autoantibodies markers for beta-cell autoimmunity, and recruitment rates for both the screening and for the intervention trial.

  Eligibility

Ages Eligible for Study:   up to 4 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HLA genotypes that increase risk of type 1 diabetes: heterozygous for DRB1*03, DQA1*0501, DQB1*0201 / DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 ≠ *0403 or related alleles), or homozygous for DRB1*03, DQA1*0501, DQB1*0201, or homozygous for DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 ≠ *0403 or related alleles).

Exclusion Criteria:

  • Premature, low birthweight, or major congenital malformations or serious chronic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141986

Locations
Canada, Manitoba
Manitoba Institute of Child Health
Winnipeg, Manitoba, Canada
Sponsors and Collaborators
Canadian Diabetes Association
Manitoba Medical Service Foundation
Manitoba Institute of Child Health
The Health Sciences Centre Medical Staff Council
Investigators
Principal Investigator: Shayne P Taback, MD FRCPC University of Manitoba
  More Information

Publications:
Responsible Party: Shayne P. Taback, University of Manitoba
ClinicalTrials.gov Identifier: NCT00141986     History of Changes
Other Study ID Numbers: 1622
Study First Received: September 1, 2005
Last Updated: April 25, 2011
Health Authority: Canada: Health Canada

Keywords provided by Canadian Diabetes Association:
vitamin D
type 1 diabetes
prevention trial

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Cholecalciferol
Vitamin D
Ergocalciferols
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on July 20, 2014